Cellectis S.A. - stock earnings
CLLS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q3 | -17.5 million USD | 155000 USD |
| 2023Q2 | -10.6 million USD | 178000 USD |
| 2023Q1 | -30.1 million USD | 139000 USD |
| 2022Q4 | -25.7 million USD | 16.0 million USD |
| 2022Q3 | -24.7 million USD | 217000 USD |
| 2022Q2 | -18.9 million USD | 1.3 million USD |
| 2022Q1 | -31.9 million USD | 1.7 million USD |
| 2021Q4 | -40.6 million USD | 13.6 million USD |
| 2021Q3 | -37.4 million USD | 8.3 million USD |
| 2021Q2 | -39.9 million USD | 11.2 million USD |
| 2021Q1 | -11.9 million USD | 25.6 million USD |
| 2020Q4 | -40.6 million USD | 13.6 million USD |
| 2020Q3 | -30.3 million USD | 6.2 million USD |
| 2020Q2 | -32.3 million USD | 2.9 million USD |
| 2020Q1 | 20.1 million USD | 50.1 million USD |
| 2019Q4 | -37.2 million USD | 4.4 million USD |
| 2019Q3 | -16.0 million USD | 8.5 million USD |
| 2019Q2 | -33.4 million USD | 1.2 million USD |
| 2019Q1 | -15.2 million USD | 1.0 million USD |
| 2018Q4 | -23.1 million USD | 968000 USD |
| 2018Q3 | -22.8 million USD | 905000 USD |
| 2018Q2 | -7.3 million USD | 5.0 million USD |
| 2018Q1 | -25.4 million USD | 6.0 million USD |
| 2017Q4 | -27.2 million USD | 5.7 million USD |
| 2017Q3 | -26.2 million USD | 6.1 million USD |
| 2017Q2 | -27.6 million USD | 6.8 million USD |
| 2017Q1 | -19.8 million USD | 6.8 million USD |
| 2016Q4 | -13.1 million USD | 8.0 million USD |
| 2016Q3 | -14.1 million USD | 11.3 million USD |
| 2016Q2 | -7.0 million USD | 17.6 million USD |
| 2016Q1 | -33.4 million USD | 7.9 million USD |
| 2015Q4 | 9.0 million USD | 29.5 million USD |
| 2015Q3 | -14.4 million USD | 8.6 million USD |
| 2015Q2 | -24.9 million USD | 8.2 million USD |
| 2015Q1 | 6.7 million USD | 9.1 million USD |
| 2014Q4 | 10.2 million USD | 15.9 million USD |
| 2014Q3 | ? USD | 10.3 million USD |
| 2014Q2 | ? USD | 10.3 million USD |
| 2013Q4 | -55.4 million USD | 7.4 million USD |
| 2012Q4 | -31.1 million USD | 21.6 million USD |
CLLS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -85.0 million USD | 16.5 million USD |
| 2022 | -98.7 million USD | 19.2 million USD |
| 2021 | -86.3 million USD | 73.9 million USD |
| 2020 | -72.6 million USD | 73.9 million USD |
| 2019 | -90.7 million USD | 15.2 million USD |
| 2018 | -78.7 million USD | 12.7 million USD |
| 2017 | -99.4 million USD | 25.2 million USD |
| 2016 | -63.9 million USD | 42.6 million USD |
| 2015 | -22.5 million USD | 55.0 million USD |
| 2014 | 24320 USD | 26.3 million USD |
| 2013 | -84.3 million USD | 22.8 million USD |
| 2012 | -29.5 million USD | 27.8 million USD |
| 2011 | -30.9 million USD | 20.7 million USD |
| 2010 | -10.7 million USD | 21.0 million USD |
| 2009 | -5.5 million USD | 17.3 million USD |
| 2008 | 185149 USD | 14.8 million USD |
| 2007 | -4.4 million USD | 4.1 million USD |
CLLS
Price: $2.99
52 week price:
Earnings Per Share: -1.41 USD
P/E Ratio: -2.13
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.9 million
Ebitda: -29.3 millionMarket Capitalization: 193.0 million